Anti-SLAMF7 CAR T Cells


The National Cancer Institute (NCI) has constructed a novel anti-SLAMF7 CAR T cell therapy that can specifically recognize SLAMF7- expressing target cells and eradicate SLAMF7-expressing tumors in mice.

SparkCures ID 342
Generic Name Anti-SLAMF7 CAR T Cells
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)


There are no resources, links or videos to display for this treatment.